Business
Bonus Biogroup Announces U.S. Food and Drug Administration (FDA) Clearance of an Investigational New Drug (IND) Application for MesenCure™ Phase III Clinical Study in Respiratory Distress
The Company is working to expand its indication to include patients who have respiratory distress from any cause, including acute respiratory distress syndrome (ARDS) MesenCure's market potential in all-cause ARDS in the United States alone could reach approximately $9.6 billion by 2030, according to Company estimates TEL AVIV, Israel, Feb. 20, 2025 (GLOBE NEWSWIRE) -- Bonus Biogroup (TASE: BONS), a late-stage biotechnology company priming immunomodulatory and regenerative mesenchymal stromal ce
About this update from Bonus Biogroup Ltd.
[{"type":"image","alt":"Bonus Biogroup","displaySize":"","headline":null,"caption":"Bonus Biogroup","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":137,"url":"https://media.zenfs.com/en/globenewswire.com/865d3a5d03479ba88a766a031c7653cb"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/lV6Zek5WuKuZNna_1PSpeQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE5MjtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/865d3a5d03479ba88a766a031c7653cb","width":300,"height":137}},"lazy":false},{"type":"text","content":"The Company is working to expand its indication to include patients who have respiratory distress from any cause, including acute respiratory distress syndrome (ARDS)","length":166,"tagName":"p"},{"type":"text","content":"MesenCure's market potential in all-cause ARDS in the United States alone could reach approximately $9.6 billion by 2030, according to Company estimates","length":156,"tagName":"p"},{"type":"text","content":"TEL AVIV, Israel, Feb. 20, 2025 (GLOBE NEWSWIRE) -- Bonus Biogroup (TASE: BONS), a late-stage biotechnology company priming immunomodulatory and regenerative mesenchymal stromal cells (MSC) to develop novel tissue engineering and cell therapy solutions, today announced that it has received U.S. Food and Drug Administration (FDA) clearance to proceed with a Phase III clinical study in the United States to evaluate the efficacy and safety of MesenCure™ (allogeneic cell therapy consisting of enhanced adipose tissue-derived MSC) to treat respiratory distress in hospitalized, severely ill patients resulting from pneumonia related to COVID-19. MesenCure is an enhanced cell therapy developed by Bonus Biogroup for treating inflammation and tissue damage.","length":756,"tagName":"p"},{"type":"text","content":"The Company is working to expand the Phase III clinical study indication to include the treatment of respiratory distress that manifests from any cause, including acute respiratory distress syndrome (ARDS), based on clinical and preclinical findings indicating MesenCure's potential in treating this indication, regardless of its underlying etiology. The IND application is supported, among other factors, by results from a Phase II clinical study of MesenCure completed in 2022. This study demonstrated approximately 68% reduction in the 30-day all-cause mortality rate among hospitalized, severely ...